Investing.com -- Spanish pharmaceutical company Laboratorios Farmaceuticos Rovi on Thursday reported first-half 2025 results in line with sales consensus and 4% above consensus at the EBITDA level.

For the third quarter, Robert Half expects overall revenue to decline by about 8% year-over-year to $1.36 billion at the midpoint of guidance. The company anticipates its Protiviti consulting division ...

Investing.com -- STMicroelectronics (EPA: STMPA) on Thursday reported a net loss of $97 million for the second quarter of ...

The Swiss company maintained its 2025 outlook, saying it still expects organic sales growth to improve and estimates an ...

Growing use of artificial intelligence in advertising is expected to boost the global entertainment and media industry’s ...